Skip to main content

RheumNow Podcast – The End of Arthritis (9.13.19)

Sep 13, 2019 1:21 am

Dr. Jack Cush reviews the news and journal articles from the past week on

  1. TICOPA study was a T2T strategy trial in psoriatic arthritis to improve outcomes. 5 yr outcomes of 110 pts shows simlar low Dz activity in TC 69% vs SOC 76%. Biologic use was higher in TC ( 33%). Not much advantage to TC - just more biologics and less MTX   
  2. UK Clinical Practice Database compared 68,897 gout pts vs 554,964 without gout, showing gout doubles risk of (8.5/1000PY vs 4.1/1000PY w/o gout). Risk highest with ESRD. Gout did not increase CKD related deaths.
  3. Based on a literature review, the prevalence of AA Amyloidosis in Adult onset Still's dz was 0.88%. 16 pt review showed mean age at AOSD onset was 30 yrs & a mean delay before AAA diagnosis of 16.75 yrs. Renal involvement was most common AAA feature.
  4. A changing spectrum of Hydralazine induced lupus? Several reports showing cases of the usual (pleuropericarditis, arthriti + Skin, +ANA) but also the unusual (ANA neg, ANCA/PR3/MPO positive, Bx proven nephritis and +ACL, +dsDNA)
  5. VA study of RA pts (2002-12) shows persistence on Rx at 1 year was 45% in for MTX- TNFi (n = 2,125) and 18% for triple therapy (MSH) (n = 171) (P
  6. FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD) PI:
  7. Two vs. Four Weeks of Antibiotic Therapy in Septic  Arthritis  
  8. Bimekizumab Add-on Therapy in Rheumatoid Arthritis  
  9. Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement 

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.